News & Views
News & Views
Iksuda receives US FDA IND clearance for IKS04
CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’, is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads
Iksuda receives US FDA IND clearance for IKS04
CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’, is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads
Iksuda to present preliminary analysis of oesophageal cancer data from Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium
Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy that included a trastuzumab component in at least one prior treatment
WADC Award November 2025
World ADC is considered the premier global conference for end-to-end ADC innovation and success, and is the world's largest, definitive and longest standing ADC forum. IKS014 was selected based on excellent data from the ongoing Phase 1 clinical trial assessing safety and efficacy in HER2+ and HER2-low solid tumors.
Iksuda presents encouraging IKS014 Phase 1 data at ESMO
New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study Anti-tumour activity observed across all dose levels and in various tumour indications
Iksuda to present IKS014 Phase 1 data at ESMO
Newcastle, UK, 14 October 2025: Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2) ADC, in patients with advanced HER2+ solid tumours, at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany (17-21 October).
Iksuda share paper via AACR
Iksuda Therapeutics are pleased to share that our paper "IKS04, a CanAg-Targeting Antibody-Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models" has been published via AACR Journals.